Aptalis Pharma and Gilead have co-developed the oral powder formulation of Viread using the Aptalis Microcaps taste-masking technology.
The Aptalis microencapsulation technology, known as Microcaps, employs versatile and precise coating techniques to encapsulate individual drug particles using solvent- and aqueous-based coacervation.
Gilead will be responsible for the product commercialization, while Aptalis will manufacture and supply the oral powder to Gilead.